MA30600B1 - Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique. - Google Patents

Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique.

Info

Publication number
MA30600B1
MA30600B1 MA31588A MA31588A MA30600B1 MA 30600 B1 MA30600 B1 MA 30600B1 MA 31588 A MA31588 A MA 31588A MA 31588 A MA31588 A MA 31588A MA 30600 B1 MA30600 B1 MA 30600B1
Authority
MA
Morocco
Prior art keywords
phenethyl
amino
carboxybutyl
methyl
benzoic acid
Prior art date
Application number
MA31588A
Other languages
English (en)
Inventor
Bernd Kuehn
Daniel Wagner
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA30600B1 publication Critical patent/MA30600B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formulation médicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phénéthylbenzyl)oxyl-phénéthyl}amino)méthyl]benzoïque La présente invention concerne une formulation médicamenteuse aqueuse contenant de l'acide 4-{((4-carboxybutyl)-{2-[(4-phénéthylbenzyl)oxy]phénéthyl}amino)méthyl]benzoïque ou un sel de celui-ci. En particulier, la présente invention concerne une composition médicamenteuse aqueuse contenant de l'acide 4-[((4-carboxybutyl)-{2-[(4-phénéthylbenzyl)oxy]phénéthyl}amino)méthyl]benzoïque ou un sel de celui-ci et du amino-2(hydroxyméthyl)-2-propanediol-1,3(trométamol).
MA31588A 2006-07-06 2009-01-27 Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique. MA30600B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006031175A DE102006031175A1 (de) 2006-07-06 2006-07-06 Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur

Publications (1)

Publication Number Publication Date
MA30600B1 true MA30600B1 (fr) 2009-07-01

Family

ID=38330492

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31588A MA30600B1 (fr) 2006-07-06 2009-01-27 Formulation medicamenteuse aqueuse d'acide 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl]benzoique.

Country Status (33)

Country Link
US (1) US20100069493A1 (fr)
EP (1) EP2040691B1 (fr)
JP (1) JP2009542589A (fr)
KR (1) KR20090031546A (fr)
CN (1) CN101484154A (fr)
AR (1) AR061812A1 (fr)
AT (1) ATE511837T1 (fr)
AU (1) AU2007271431A1 (fr)
BR (1) BRPI0714012A2 (fr)
CA (1) CA2656630A1 (fr)
CL (1) CL2007001960A1 (fr)
CO (1) CO6160303A2 (fr)
CR (1) CR10550A (fr)
CY (1) CY1111881T1 (fr)
DE (1) DE102006031175A1 (fr)
DK (1) DK2040691T3 (fr)
EC (1) ECSP089023A (fr)
ES (1) ES2366389T3 (fr)
GT (1) GT200800310A (fr)
IL (1) IL195970A0 (fr)
MA (1) MA30600B1 (fr)
MX (1) MX2009000012A (fr)
PE (1) PE20080554A1 (fr)
PL (1) PL2040691T3 (fr)
PT (1) PT2040691E (fr)
RU (1) RU2009103818A (fr)
SI (1) SI2040691T1 (fr)
SV (1) SV2009003143A (fr)
TN (1) TNSN08517A1 (fr)
TW (1) TW200808690A (fr)
UA (1) UA94955C2 (fr)
UY (1) UY30471A1 (fr)
WO (1) WO2008003414A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2115213A1 (fr) * 2007-02-08 2009-11-11 Dow Global Technologies Inc. Feuille polymère conductrice flexible
DE102008062689A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Modifikation I der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
DE102008062688A1 (de) * 2008-12-17 2010-06-24 Bayer Schering Pharma Aktiengesellschaft Monohydrat der 4-({(4-Carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]-amino}methyl)benzoesäure
HUE053745T2 (hu) 2011-11-25 2021-07-28 Adverio Pharma Gmbh Helyettesített 5-fluor-1H-pirazolopiridin kristályos formában
PL2875003T3 (pl) * 2012-07-20 2017-05-31 Bayer Pharma Aktiengesellschaft Nowe kwasy 5-aminotetrahydrochinolino-2-karboksylowe i ich zastosowanie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4698361A (en) * 1986-05-28 1987-10-06 Schiena Michele G Di Tris-chydroxymethyl) aminomethane salt of 4-chloro-N-furfuryl-5-sulfamoyl anthranilic acid and diuretic compositions containing the same
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination

Also Published As

Publication number Publication date
IL195970A0 (en) 2009-09-01
ECSP089023A (es) 2009-01-30
PT2040691E (pt) 2011-08-23
ES2366389T3 (es) 2011-10-19
CA2656630A1 (fr) 2008-01-10
PE20080554A1 (es) 2008-07-13
US20100069493A1 (en) 2010-03-18
AU2007271431A1 (en) 2008-01-10
RU2009103818A (ru) 2010-08-20
CN101484154A (zh) 2009-07-15
MX2009000012A (es) 2009-01-23
CO6160303A2 (es) 2010-05-20
JP2009542589A (ja) 2009-12-03
CY1111881T1 (el) 2015-11-04
ATE511837T1 (de) 2011-06-15
EP2040691A1 (fr) 2009-04-01
SV2009003143A (es) 2009-07-28
PL2040691T3 (pl) 2012-01-31
SI2040691T1 (sl) 2011-10-28
TW200808690A (en) 2008-02-16
CL2007001960A1 (es) 2008-02-01
UA94955C2 (en) 2011-06-25
AR061812A1 (es) 2008-09-24
UY30471A1 (es) 2008-02-29
DK2040691T3 (da) 2011-09-26
KR20090031546A (ko) 2009-03-26
WO2008003414A1 (fr) 2008-01-10
TNSN08517A1 (en) 2010-04-14
CR10550A (es) 2009-06-04
GT200800310A (es) 2009-07-31
BRPI0714012A2 (pt) 2013-04-02
EP2040691B1 (fr) 2011-06-08
DE102006031175A1 (de) 2008-01-10

Similar Documents

Publication Publication Date Title
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
PE20050018A1 (es) Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b)
BRPI0609636A2 (pt) formulações farmacêuticas
BRPI0407845A (pt) formulação intranasal de rotigotina
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
CY1114118T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λουρασιδονη
BR0315264A (pt) Comprimidos dispersáveis de deferasirox
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200702498A1 (ru) N-(пиридин-2-ил)сульфонамидные производные
DE602005025755D1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
EE200100104A (et) 5-HT4 agonisti või antagonisti uus peroraalne ravimvorm
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
BR0115518A (pt) Kit de repinotan
ATE501121T1 (de) 4-ä(3- fluorphenoxy)phenylmethylüpiperidinmethandsulfo atverwendungen, syntheseverfahren und pharmazeutische zusammensetzungen
UA94955C2 (en) Aqueous pharmaceutical formulation of 4-[((4-carboxybutyl)-{2-[(4-phenethyl-benzyl)oxy]-phenethyl}amino)methyl] benzoic acid
ATE440838T1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
BRPI0613664A8 (pt) antagonista de 3-lactamil fenilalanina,cisteína e serina vasopressina
MX2007009142A (es) Formulaciones y regimen de dosificacion para modulares ppar-alfa.
UY28371A1 (es) Agentes terapéuticos
DE602005020314D1 (de) Bicyclononen-derivate als renin-inhibitoren
MA27731A1 (fr) Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete
ATE435006T1 (de) Pharmazeutisches präparat für die mundhöhle